EverythingALS and CureALS Join Forces to Discover a Cure for ALS
Retrieved on:
Tuesday, July 11, 2023
Technology, Research, Neurology, Professional Services, Biotechnology, Health, Data Analytics, Science, Artificial Intelligence, Frontotemporal dementia, Partnership, Stage 4, Therapy, ALS, Cureall, Missouri, History, Government, Organization, Acquisition, Patient, Amyotrophy, Artificial intelligence, Diagnosis, Ecosystem, AI, FTD, Data science, Retail, Management, Pharmaceutical industry, Indu
EverythingALS and CureALS, two prominent organizations dedicated to finding a cure for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD), are thrilled to announce their merger and unified operations on the EverythingALS platform.
Key Points:
- EverythingALS and CureALS, two prominent organizations dedicated to finding a cure for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD), are thrilled to announce their merger and unified operations on the EverythingALS platform.
- Both EverythingALS and CureALS have identified key areas of alignment that have propelled this unification, based on a common vision, and understanding of the challenges faced in the cure of ALS.
- Expressing her confidence in the merger, Indu stated, "CureALS is EverythingALS's vehicle to focus on research to discover a cure, without overlap in approach.
- The merger between EverythingALS and CureALS represents a significant leap forward in the pursuit of a cure for ALS and FTD.